Coripharma is a European pharmaceutical company, built on solid heritage. Our experienced team offers out-licensing and contract manufacturing services to pharmaceutical companies. Coripharma specializes in generic pharmaceutical products, solid oral dosage forms.

Coripharma

Margret has extensive experience in the pharmaceutical Industry having worked as the Quality Manager of Florealis and prior to that being a Qualified Person at Actavis.

Margret holds a PhD in Medical Life Science from the University of Iceland as well as a master’s degree in pharmacology.

“It is very exciting to get the opportunity to lead the Quality operations at Coripharma. I look forward to continuing working with the quality team to strengthen our quality management system to ensure that we remain competitive and responsive so we can meet customers’ requirements and regulatory standards”.

Dr. Margret Bessadottir

“At Coripharma we are fortunate to have a great group of people working with us and to have the opportunity to promote within. Margret has been a strong part of our team, leading the Quality Control department in the past, now stepping up to head our Quality Operations. It’s imperative to a company like ours to maintain the highest standard of quality in all aspects and I’m confident that Margret is exactly the right person to oversee that.”

Jonina Gudmundsdottir

Coripharma is a pharmaceutical company that specializes in development, manufacturing, and exporting of generic pharmaceuticals. Coripharma employs around 190 people.

Dr. Margret Bessadottir has been appointed Director of Quality Operations at Coripharma and will be joining the Executive Management Team.

Dr. Margret Bessadottir appointed to the role of Director of Quality Operations at Coripharma

Bio Equivalence studies for Ruxolitinib have passed successfully and we believe Coripharma is among the front runners in developing the generic product. The dossier is set to be completed in Q1 2024, pending stability studies.

The progress of development has been excellent, and we are thankful for our great team and their superb efforts. 

If you want to join our journey, please reach out to our commercial team.

Ruxolitinib is indicated to treat Myelofibrosis and is based on the reference product Jakavi®.

Ruxolitinib development in final stages. Dossier availability in Q1 2024, with DCP slots in April

Ludvik Karl Tomasson takes on the role of CFO from Agust Helgi Leosson, who recently decided to take on a different role within the company’s finance department.

Ludvik has decades of experience in international finance and financial reporting in pharmaceutical and biotechnology companies; most recently with Hansa Biopharma AB in Sweden and previously with TFS International AB, Alvogen, Inc and DeCODE Genetics.

Ludvik is a certified CPA and holds an Executive MBA degree from Columbia Business School, New York, and London Business School.

“I’m very happy and proud to have been given the opportunity and I look forward to assuming this responsibility and continue to build on the strong foundation already established. There are exciting times ahead, new products are entering the market, preparations for the upcoming IPO, as well as introducing new systems and processes to support the future growth of the company”.

Ludvik Karl Tomasson

Stefan Thor Arnarsson has been appointed Director of a newly implemented Supply Chain division.

Stefan joined Coripharma in 2021 as a Business Development Manager. Stefan has 16 years of experience in supply chain management in the pharmaceutical industry. For the majority of that time Stefan worked for Medis as a Director in the supply chain, as well as being the deputy to the VP of Supply Chain Operations. Stefan holds a B.Sc. degree in Business Administration and Supply Chain Management from the University of Reykjavik.

“It’s a great honour to get the opportunity to lead the newly founded Supply Chain division at Coripharma. The company is growing and exciting times are ahead in the structuring of the company. We have a lot to gain by solidifying a smooth and efficient supply chain and I look very much forward to taking on the upcoming tasks with our excellent Coripharma team”.

Stefan Thor Arnarsson

“Coripharma aims to double its revenue from pharmaceutical exports this year, our development of generic pharmaceutical is going very well, and we have already secured agreements with many of the top European generic pharmaceutical companies. Therefore, it’s very important that the organisational structure is dynamic, reflects the rapid growth of the company and making sure we have the right people in key positions. I’m very pleased to have Ludvik Karl and Stefan Thor joining our Executive Management Team and I’m certain that their extensive knowledge and experience will be valuable assets to the company”.

Jonina Gudmundsdottir, CEO

Two new executives, Ludvik Karl Tomasson and Stefan Thor Arnarsson, have taken a seat in Coripharma‘s Executive Management Team. Ludvik has been appointed to the position of CFO and Stefan Thor has been appointed to a newly formed role as Director of Supply Chain Operations.

Changes in Coripharma‘s Executive Management Team

Coripharma proudly announces the completion of the 16th dossier from its own development, marking a significant milestone in the company’s journey of innovation and excellence.

Lisdexamphetamine is based on the reference product Elvanse®, commonly prescribed for managing attention deficit disorder (ADHD).

This achievement is a testament to the outstanding efforts of the R&D team and the seamless collaboration within Coripharma. The timing couldn’t be better, as the secured DCP slot in January 2025 strategically positions our partners for successful market entry.

With this milestone, Coripharma reaffirms its dedication to development of high-quality generics and strengthens its global partnerships.

Coripharma Completes Lisdexamphetamine Dossier, Secures DCP Slot for January 2025

About us

Services

Sustainability

Careers

Coripharma Completes Lisdexamphetamine Dossier, Secures DCP Slot for January 2025

More news

Dr. Margret Bessadottir appointed to the role of Director of Quality Operations at Coripharma

Ruxolitinib development in final stages. Dossier availability in Q1 2024, with DCP slots in April

Changes in Coripharma‘s Executive Management Team

+354 4206700